Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Pembrolizumab Plus Chemotherapy Shows Preliminary Activity in Advanced Penile Cancer

October 2nd 2025

The addition of the PD-1 inhibitor to platinum-based chemotherapy demonstrated proof of concept for the use of chemoimmunotherapy in patients with PSCC.

AMXT 1501 Plus Difluoromethylornithine Nets FDA Orphan Drug Designation in Neuroblastoma

October 2nd 2025

AMXT 1501 plus difluoromethylornithine has received orphan drug designation from the FDA in patients with neuroblastoma.

Inside the Most Anticipated Lung Cancer Abstracts: What to Expect From ESMO 2025

October 2nd 2025

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

Dual-Binding XmAb30819 Shows Strong Specificity in ENPP3-Positive RCC

October 1st 2025

ENPP3 offers a potentially attractive treatment target in patients with clear cell RCC.

How AI-Driven Platforms Can Transform Clinical Trial Efficiency in Cancer Care

October 1st 2025

Katie Goodman, RN, BSN, discusses the ways in which artificial intelligence can help speed up the pace of clinical trial accrual

Dr Dietrich on the Limitations of Chemotherapy in Pancreatic Cancer

September 30th 2025

Martin F. Dietrich, MD, PhD, discusses the limitations of frontline chemotherapy in advanced/metastatic pancreatic cancer.

Predictors of cGVHD Outcomes Remain Elusive in Pediatric Hematologic Malignancies

September 29th 2025

Acute GVHD was shown to be a risk factor for chronic GVHD, but factors such as organ involvement showed no correlation with long-term outcomes.

Recognizing the Rapidly Changing World of Surgical Oncology

September 29th 2025

Maurie Markman, MD, discusses the evolution of surgical oncology, from radical resections to multidisciplinary, minimally invasive, and neoadjuvant approaches.

From Overload to Insight: Why AI Is Becoming an Essential Partner in Oncology

September 28th 2025

Brian P. Mulherin, MD, discusses how artificial intelligence is helping shape smarter cancer care.

Simplifying Care Navigation in Oncology: A Painless Path to Better Support

September 28th 2025

Lalan Wilfong, MD, discusses the patient- and provider-facing implications that may result from renewed focus on improving care navigation in oncology.

Flora Charts the Future of AI in Community Cancer Care

September 27th 2025

Doug Flora, MD, FACC, LSSBB, explains how AI is transforming cancer care, urging oncologists to engage and guide its responsible use.

Sunvozertinib Approval Fills Treatment Gap in Pretreated EGFR Exon 20–Mutant NSCLC

September 26th 2025

Lyudmila A. Bazhenova, MD, discusses the FDA approval of sunvozertinib (Zegfrovy) in patients with EGFR exon 20–mutant non–small cell lung cancer.

Pirtobrutinib Offers Potential Second-Line Treatment in CLL

September 26th 2025

Jennifer A. Woyach, MD, discusses the potential of pirtobrutinib as a second-line option for patients with CLL.

First-Line Atebimetinib Plus mGnP Yields High 9-Month OS Rate in Pancreatic Cancer

September 25th 2025

Atebimetinib plus modified gemcitabine/nab-paclitaxel continued to elicit high OS rates in patients with treatment-naive pancreatic cancer.

FDA Grants Fast Track Designation to Alnodesertib Plus Irinotecan in ATM-Negative mCRC

September 24th 2025

Alnodesertib has received fast track designation from the FDA for patients with ATM-negative metastatic colorectal cancer.

FDA Grants Priority Review to First-Line T-DXd Plus Pertuzumab in Metastatic HER2+ Breast Cancer

September 24th 2025

Frontline T-DXd plus pertuzumab is under FDA priority review for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

Personalized Approaches Are Emerging for GVHD in Hematologic Malignancies

September 24th 2025

A panel of hematologic cancer experts discusses data on GVHD management from the 2025 SOHO Annual Meeting.

Linvoseltamab Adds Highly Effective Option in Later-Line Multiple Myeloma

September 23rd 2025

Hans Lee, MD; and Nisha Joseph, MD, discuss the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

New T-DXd Data Have the Potential to Reorder ADC Sequencing in HER2+ Breast Cancer

September 22nd 2025

Naoto T. Ueno, MD, PhD, FACP, discusses treatment sequencing considerations in HER2+ advanced or metastatic breast cancer.

Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma

September 20th 2025

Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.